IMVT vs. KRYS, IOVA, CRSP, SWTX, HALO, IMCR, IBRX, ACLX, UTZ, and TWST
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Krystal Biotech (KRYS), Iovance Biotherapeutics (IOVA), CRISPR Therapeutics (CRSP), SpringWorks Therapeutics (SWTX), Halozyme Therapeutics (HALO), Immunocore (IMCR), ImmunityBio (IBRX), Arcellx (ACLX), Utz Brands (UTZ), and Twist Bioscience (TWST).
Krystal Biotech (NASDAQ:KRYS) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
Krystal Biotech has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
Krystal Biotech currently has a consensus price target of $171.00, suggesting a potential upside of 8.23%. Immunovant has a consensus price target of $48.00, suggesting a potential upside of 61.62%. Given Krystal Biotech's higher possible upside, analysts clearly believe Immunovant is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 25 more articles in the media than Immunovant. MarketBeat recorded 30 mentions for Krystal Biotech and 5 mentions for Immunovant. Krystal Biotech's average media sentiment score of 1.09 beat Immunovant's score of 0.36 indicating that Immunovant is being referred to more favorably in the news media.
Krystal Biotech has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Immunovant's return on equity of -13.31% beat Krystal Biotech's return on equity.
Krystal Biotech received 169 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 66.83% of users gave Krystal Biotech an outperform vote.
Summary
Krystal Biotech beats Immunovant on 11 of the 15 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
